TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04694495

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene sequencing of cervical secretions
Description: 1. 16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~2. Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~3. Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~4. Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene sequencing of cervical secretions
Description: 1. 16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~2. Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~3. Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~4. Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia
Study: NCT05815407

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02086786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM
Description: Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM
Description: Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals.
Study: NCT03317795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUS
Description: LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
Study: NCT04383860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5-0 suture
Description: 5-0 suture administration during surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4-0 suture
Description: 4-0 suture administration during surgery
Study: NCT03187431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mesenchymal stem cells
Description: intravenous infusion
Study: NCT02189161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (Barrx™)
Description: Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
Study: NCT03412175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: The CREATION Health Specialist (CHS) will review with the participant his/her biometrics, assessments, and surveys. The CHS will identify the participant's strengths and weaknesses thereby tailoring the intervention care plan to the participant. Together the participant and CHS will work on goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, and self-regulatory techniques.
Study: NCT04811456

Intervention type: OTHER
Intervention: multisystem inflammatory syndrome in children (MIS-C)
Description: as in group description
Study: NCT02897700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate
Description: Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)
Description: Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
Study: NCT01347554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus eluting stent
Description: Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
Study: NCT03058042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises of the pelvic floor muscle at home
Description: Patients will perform pelvic floor exercises at home.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercises of the pelvic floor muscle in the outpatient
Description: Patients will perform pelvic floor exercises in the outpatient.
Study: NCT00812058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG2417
Description: 1g bid dose escalates to 2g bid for weeks 2-8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
Study: NCT01880931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The effect site concentration of remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The effect site concentration of remifentanil
Study: NCT03027531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eKISS: electronic KIOSK for Safer-Sex
Description: An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eKISS: electronic KIOSK for Safer-Sex
Description: An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
Study: NCT02832973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide,
Description: Furosemide 20-40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 5-10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol 5-10 mg
Study: NCT03448068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care
Study: NCT02326454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talaporfin sodium
Description: 1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talaporfin sodium
Description: 1 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Drug Activator 100 J/cm
Description: Light Dose: 100 J/cm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Activator 100 J/cm
Description: Light Dose: 100 J/cm

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Drug Activator 200 J/cm
Description: Light Dose: 200 J/cm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Activator 200 J/cm
Description: Light Dose: 200 J/cm
Study: NCT03893968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information by an assistant nurse
Description: Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information by a doctor
Description: Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
Study: NCT01888640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS Parameters: Active TENS and Placebo TENS~* TENS Frequency - 2-125 Hz~* TENS Pulse Width - 200 µs~* TENS Intensity - Maximal tolerable intensity~* Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~* Administration - Daily~* TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: TENS Parameters: Active TENS and Placebo TENS~* TENS Frequency - 2-125 Hz~* TENS Pulse Width - 200 µs~* TENS Intensity - Maximal tolerable intensity~* Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~* Administration - Daily~* TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care
Study: NCT03669458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below the Knee peripheral intervention
Description: Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below the Knee peripheral intervention
Description: Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below the Knee peripheral intervention
Description: Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
Study: NCT01342835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
Study: NCT01227044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Medication Management/Medication Coaching
Description: Placebo + Medication Management/Medication Coaching
Study: NCT02250274

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: LAIV
Description: Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IIV
Description: A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~\[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.\]
Study: NCT00473343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix® cream
Study: NCT03121404

Intervention type: PROCEDURE
Intervention: Rectus abdominis muscle biopsy
Description: Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.

Intervention type: PROCEDURE
Intervention: Rectus abdominis muscle biopsy
Description: Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
Study: NCT03256500

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
Study: NCT01079897

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atopiclair
Description: topical applied cream, twice daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EHK02-01
Description: topical applied cream containing 7% ectoine
Study: NCT03518593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash and counselling
Description: Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
Study: NCT02755311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver resection
Description: Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization
Description: A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipiodol
Description: Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil
Description: The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: absorbable gelatin sponge particles
Description: Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
Study: NCT03891264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
Study: NCT01446406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MONARCA
Description: Monitoring affective symptoms entered by the patient every day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NON-MONARCA
Description: A mobile phone for communication purposes only. No application has been installed.
Study: NCT00574275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
Study: NCT00644774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: 2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 2.5 ml of cherry flavored oral suspension 100 mg/5 ml